Investors
We are committed to delivering our strategy and creating value for our shareholders.
Verona Pharma can make real a difference to the COPD market, believes CEO Jan-Anders Karlsson
Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.
Watch Jan-Anders Karlsson on Proactive Investors
Latest News
Latest Events
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life Conference call scheduled
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
Data release and conference call on Monday January 13, 2020 LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved